Brak połączenia z internetem — wyświetlanie zapisanej wersji strony.

Neurocrine Biosci…

USUSD
← Do screenera

Neurocrine Biosciences Inc (US:NBIX) — Biotechnology: Biological Products (No Diagnostic Substances). Liczba giełd, na których notowane są akcje spółki: 3. Na tej stronie — cena i wykres, dywidendy, najwięksi akcjonariusze oraz historia liczby akcji.

O firmie

Strona
neurocrine.com
Sektor
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Siedziba
San Diego, United States
Prezes
Kyle W. Gano
Pracownicy
2 500
Założona
1992
Akcje w obrocie
101.65 mln na 2026-07-22
Free float
100.37 mln
Kapitalizacja rynkowa
14.42 mld USD
Insiderzy
1.06%
Inwestorzy instytucjonalni
102.84%
Branża (SIC)
Biological Products, (No Diagnostic Substances)
Forma prawna
XTIQ
ISIN
US64125C1099
LEI
549300FECER0XBN49756
FCF
870 mln USD
Dług
0
Zyski i FCF — za 12 miesięcy do 30.06.2026 roku (najnowszy raport firmy).
Opis

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Giełdy i tickery

GiełdaTickerWalutaCenaTyp
US USA StocksNBIX główneUSD141.25 -1.55%akcje zwykłe
LSE London Stock Exchange0K6R IOBUSD138.12 +0.00%akcje zwykłe
MI Borsa Italiana (Milan)1NBIX dodatkoweEUR129.8 -0.15%akcje zwykłe

Cena z 3 lat (świece tygodniowe)

dzień wzrostu dzień spadkuNajedź / dotknij dnia — ceny otwarcia, zamknięcia, najwyższa i najniższa

Wiadomości w tym tygodniu

Brak jeszcze wiadomości ze strony spółki.

reklama

Najwięksi akcjonariusze

PosiadaczUdziałAkcjeData raportu
Blackrock Inc.13.49%13.71 mln2026-06-30
JPMORGAN CHASE & CO6.29%6.4 mln2026-06-30
Dodge & Cox Inc.5.49%5.58 mln2026-06-30
Vanguard Portfolio Manag…4.89%4.97 mln2026-06-30
Vanguard Capital Managem…4.47%4.55 mln2026-06-30
State Street Corporation4.31%4.39 mln2026-06-30
Dodge & Cox Funds-Dodge…3.9%3.96 mln2026-06-30
AQR Capital Management,…3.76%3.82 mln2026-06-30
iShares Trust-iShares Co…3.46%3.52 mln2026-08-31
VANGUARD INDEX FUNDS-Van…3.14%3.19 mln2026-06-30
Renaissance Technologies…2.3%2.34 mln2026-06-30
VANGUARD INDEX FUNDS-Van…2.27%2.3 mln2026-06-30
Geode Capital Management…2.1%2.14 mln2026-06-30
Two Sigma Investments, L…2.04%2.08 mln2026-06-30
J.P. Morgan Mutual Fd. I…1.34%1.36 mln2026-06-30
VANGUARD INDEX FUNDS-Van…1.31%1.33 mln2026-06-30
VANGUARD INDEX FUNDS-Van…1.13%1.15 mln2026-06-30
JPMorgan Trust II-JPMorg…1.1%1.12 mln2026-06-30
iShares Trust-iShares Bi…0.73%739 6702026-08-31
SPDR S&P MIDCAP 400 ETF…0.72%735 3422026-08-31
GORMAN KEVIN CHARLES (Di…≈0.51%517 7972026-09-11
GANO KYLE W (Chief Execu…≈0.15%154 7282026-09-11
LYONS GARY A (Director)≈0.12%122 1412026-05-21
BENEVICH ERIC S. (Office…≈0.07%67 2972026-09-11
LIPPOLDT DARIN M (Office…≈0.06%56 7932026-09-11
RASTETTER WILLIAM H (Dir…≈0.04%43 6782026-05-21
ABERNETHY MATTHEW C (Chi…≈0.04%42 8082026-09-14
POPS RICHARD F (Director…≈0.04%37 7982026-05-21
ROBERTS EIRY WYN (Office…≈0.04%35 6402025-02-14
COOKE JULIE SMITH (Offic…≈0.02%24 0252026-09-11